Pharmacogenomics of drug efficacy in the interferon treatment of chronic hepatitis C using classification algorithms

Chronic hepatitis C (CHC) patients often stop pursuing interferon-alfa and ribavirin (IFN-alfa/RBV) treatment because of the high cost and associated adverse effects. It is highly desirable, both clinically and economically, to establish tools to distinguish responders from nonresponders and to pred...

Descripción completa

Detalles Bibliográficos
Autores principales: Ke, Wan-Sheng, Hwang, Yuchi, Lin, Eugene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170005/
https://www.ncbi.nlm.nih.gov/pubmed/21918625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170005/
https://www.ncbi.nlm.nih.gov/pubmed/21918625

Ejemplares similares